scholarly journals Correlation of GSTP1 Polymorphism with Severity of Prostate Cancer in an Eastern Indian Population

2019 ◽  
pp. 1-10
Author(s):  
Suparna Roy ◽  
Anindya Dasgupta ◽  
Subarnarekha Chatterji ◽  
Dilip Karmakar
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Odds Ratio ◽  
Indian Population ◽  
Pcr Amplification ◽  
Prognostic Indicator ◽  
Case Group ◽  
Current Case ◽  
Gstp1 Gene ◽  
Risk Of Cancer

Background: GSTP1 is one of the Glutathione-S-Transferases (GSTs) which suppress tumor genesis by detoxifying toxic carcinogens and reactive oxygen species (ROS). Prostate cancer is related to several mutations affecting the expression of GSTP1. A single nucleotide polymorphism (SNP: Ile105Val) in the GSTP1 gene results insignificant reduction in its anticancer activity. The current case control study was conducted to ascertain the risk of association of GSTP1polymorphism with risk of cancer prostate in an Eastern Indian population. Materials and Methods: During a study period of 2 years, DNA was isolated using the phenol chloroform extraction method from the blood of 225 histopathologically diagnosed prostate cancer patients and 120 matched controls. The GSTP1 polymorphism was assessed by PCR amplification of the gene followed by restriction digestion with Alw261 (a restriction enzyme derived from Acinetobactro lwoffi RFL26). Histopathological grading in the case group was performed using Gleason’s scores and International Society of Urological Pathology (ISUP) grading. Results: Comparison of the distribution of different GSTP1 alleles between the case and control groups was performed by chi square test and odds ratio analysis. A χ2 value of 18.56 suggested significantly higher number of G alleles in the case group. An odds ratio of 2.25 with a confidence interval of 1.52 to 3.34 for 95% CI showed that the G allele in GSTP1 gene were linked with greater risk of prostate cancer. Post hoc ANOVA and logistic regression suggested that cases having G alleles had more progressive form of diseases as evident from ISUP grades. Conclusion: From our study we can conclude that GSTP1 polymorphism is not only significantly associated with risk of prostate cancer but also with its severity in our Eastern Indian population. GSTP1 polymorphism should be considered as a prognostic indicator for prostate cancer patients along with planning for more aggressive management of the disease.

scholarly journals PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients

2011 ◽  
Vol 17 (20) ◽  
pp. 6563-6573 ◽  
Author(s):  
Tamara L. Lotan ◽  
Bora Gurel ◽  
Siobhan Sutcliffe ◽  
David Esopi ◽  
Wennuan Liu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Prognostic Indicator ◽  
Protein Loss ◽  
Pten Protein

Down-regulation of miR-219-5p increase the risk of cancer-related mortality in patients with prostate cancer

2021 ◽  
pp. postgradmedj-2021-139981
Author(s):  
Shimin Tang ◽  
Hao Jiang ◽  
Zhijun Cao ◽  
Qiang Zhou
Keyword(s):  
Prostate Cancer ◽  
Prediction Model ◽  
Cancer Patients ◽  
Cox Regression ◽  
Cox Model ◽  
Risk Of Death ◽  
Kaplan Meier ◽  
Risk Of Progression ◽  
Patient Prognosis ◽  
Risk Of Cancer

IntroductionProstate cancer is a common malignancy in men that is difficult to treat and carries a high risk of death. miR-219-5p is expressed in reduced amounts in many malignancies. However, the prognostic value of miR-219-5p for patients with prostate cancer remains unclear.MethodsWe retrospectively analysed data from 213 prostate cancer patients from 10 June 2012 to 9 May 2015. Overall survival was assessed by Kaplan-Meier analysis and Cox regression models. Besides, a prediction model was constructed, and calibration curves evaluated the model’s accuracy.ResultsOf the 213 patients, a total of 72 (33.8%) died and the median survival time was 60.0 months. We found by multifactorial analysis that miR-219-5p deficiency increased the risk of death by nearly fourfold (HR: 3.86, 95% CI): 2.01 to 7.44, p<0.001) and the risk of progression by twofold (HR: 2.79, 95% CI: 1.68 to 4.64, p<0.001). To quantify each covariate’s weight on prognosis, we screened variables by cox model to construct a predictive model. The Nomogram showed excellent accuracy in estimating death’s risk, with a corrected C-index of 0.778.ConclusionsmiR-219-5p can be used as a biomarker to predict death risk in prostate cancer patients. The mortality risk prediction model constructed based on miR-219-5p has good consistency and validity in assessing patient prognosis.

scholarly journals Serum Lysyl Oxidase Levels and Lysyl Oxidase Gene Polymorphism in Ovarian Cancer Patients of Eastern Indian Population

Diagnostics ◽  
2021 ◽  
Vol 12 (1) ◽  
pp. 53
Author(s):  
Suchitra Kumari ◽  
A. Raj Kumar Patro ◽  
Baijayantimala Mishra ◽  
Saubhagya Kumar Jena ◽  
Sweta Singh
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Indian Population ◽  
Lysyl Oxidase ◽  
Enzyme Linked Immunosorbent Assay ◽  
P Value ◽  
Oxidase Gene ◽  
Potential Biomarker ◽  
Control Serum ◽  
Risk Of Cancer

(1) Background: Lysyl oxidase (LOX) plays a dual role in carcinogenesis and studies show a higher risk of cancer in LOX G473A variants. The present study evaluated the pattern of LOX G473A polymorphism (rs1800449) and serum LOX levels in ovarian cancer patients. (2) Methods: Serum LOX levels were estimated by enzyme linked immunosorbent assay (ELISA). A polymorphism of rs1800449 of LOX gene was detected by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Selected samples were sequenced for external validation. (3) Results: A majority of study participants were from low socio-economic status. Serum LOX level was significantly higher in ovarian cancer patients as compared to control. Serum LOX level in early-stage ovarian cancer was significantly lower as compared to advanced stage (FIGO stage III & IV). Wild type GG genotype was used as reference. Genotypes AA were associated with a significant risk of epithelial ovarian cancer (OR 3.208; p value- 0.033). A allele of rs1800449 polymorphism of LOX gene, the odds ratio was 1.866 (95% Confidence Interval 1.112–3.16) p value = 0.017 (4) Conclusions: A allele of rs1800449 polymorphism of LOX gene presents an increased risk of ovarian cancer in East Indian population. Serum LOX levels could be a potential biomarker for the diagnosis and prognosis of ovarian cancer.

Treatment timing of life-extending therapies and adherence of corticosteroids among metastatic castration-resistant prostate cancer patients with conditions sensitive to corticosteroid use.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e16080-e16080
Author(s):  
Cat N Bui ◽  
James Spalding ◽  
Li Wang ◽  
Onur Baser
Keyword(s):  
Prostate Cancer ◽  
Vascular Disease ◽  
Cancer Patients ◽  
Peripheral Vascular Disease ◽  
Odds Ratio ◽  
Health Administration ◽  
Castration Resistant Prostate Cancer ◽  
Peripheral Vascular ◽  
Castration Resistant ◽  
Sensitive Conditions

e16080 Background: Corticosteroids (CS) have been integral in metastatic castration-resistant prostate cancer (mCRPC) treatment and can be used alongside life-extending therapies (LETs), despite potential toxicity effects. LET and CS timing and adherence were examined in CRPC patients in the Veterans Health Administration (VHA) dataset with conditions sensitive to CS use. Methods: Diagnosed prostate cancer patients with evidence of medical/surgical castration, at least two following prostate-specific antigen (PSA) increases (third PSA value date was the index), and ≥1 claim for cabazitaxel, docetaxel, or abiraterone acetate 06/2007-05/2012 were examined. Adherence was the total overlapping days of CS and LET prescriptions divided by total LET prescription days (≥0.8). Comorbid conditions were measured for 6 months pre-index date. Descriptive analysis, Cox proportional hazards, and logistic regression models summarized therapeutic/clinical features of CRPC or the CS-adherent patient subset. Results: Common CS-sensitive conditions among 15,585 mCRPC patients included hypertension (58.94%) and hyperlipidemia (42.56%). Fewer glaucoma (hazard ratio [HR]: 0.67), ischemic heart disease (HR: 0.78), and peripheral vascular disease (HR: 0.78) patients were prescribed LETs (all p<0.01). mCRPC treated patients with comorbidities (N=858) were significantly older (71.27 vs. 68.94 years, p<0.01) and more often exhibited bone metastases than those without (42.42% vs. 29.73%, p<0.01). After treatment initiation, mCRPC patients with comorbidities had a shorter LET duration (125.02 vs. 133.08 days, p=0.04) within the 6-month follow-up period. Factors associated with reduced CS adherence (≥0.8) included cerebrovascular disease (odds ratio=0.0107, 95% CI: 0.012-0.966) and peripheral vascular disease (odds ratio=0.523, 95% CI: 0.276-0.991). Conclusions: Conditions sensitive to CS influence the LET receipt and duration and are associated with lower adherence when compared to non-CS-sensitive conditions. Attention should be focused on treatments using alternatives to CS for sensitive mCRPC patients.

A review of the effects of tobacco smoking on the treatment of prostate cancer

2020 ◽  
pp. 1-8
Author(s):  
Faiza Nuru ◽  
Ernest Osei ◽  
Rahil Kassim
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Smoking Cessation ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Tobacco Smoking ◽  
Treatment Efficacy ◽  
Treatment Modalities ◽  
Risk Of Cancer

Abstract Background: Prostate cancer is the most commonly diagnosed malignancy and the third leading cause of death among Canadian men. The standard treatment modalities for prostate cancer include prostatectomy, radiation therapy, hormonal therapy and chemotherapy or any combination depending on the stage of the tumour. However, several studies have reported that tobacco smoking at the time of diagnosis and during treatment can potentially impact treatment efficacy, outcome and patients quality of life after treatment. Materials and methods: This narrative literature review elucidates the impacts of tobacco smoking on prostate cancer progression, treatment efficacy, including its effects on prostatectomy, radiation therapy and chemotherapy, risk of cancer recurrence and mortality and quality of life after treatment. Furthermore, we discuss the importance of integrating a smoking cessation programme into the treatment regimen for prostate cancer patients in order to yield more favourable treatment outcomes, reduce risk of recurrence and mortality and increase the quality of life after treatment for prostate cancer patients. Conclusions: Smoking cessation is one of the most important interventions to prevent cancer and it is also essential after the diagnosis of prostate cancer to improve clinical outcomes. All prostate cancer patients should be advised to quit tobacco use since it can potentially improve treatment response rates and survival, as well as reduce the risk of developing treatment complications and potentially improve the quality of life after treatment. There are several benefits to smoking cessation and it should become an important component of the cancer care continuum in all oncology programmes, starting from prevention of cancer through diagnosis, treatment, survivorship and palliative care. Evidence-based smoking cessation intervention should be sustainably integrated into any comprehensive cancer programme, and the information should be targeted to the specific benefits of cessation in cancer patients.

Methylation-Specific Sequencing of GSTP1 Gene Promoter in Circulating/Extracellular DNA from Blood and Urine of Healthy Donors and Prostate Cancer Patients

2008 ◽  
Vol 1137 (1) ◽  
pp. 222-225 ◽  
Author(s):  
Olga E. Bryzgunova ◽  
Evgeniy S. Morozkin ◽  
Sergey V. Yarmoschuk ◽  
Valentin V. Vlassov ◽  
Pavel P. Laktionov
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Gene Promoter ◽  
Extracellular Dna ◽  
Healthy Donors ◽  
Gstp1 Gene

scholarly journals Prostate cancer profiles and associated factors in Criciúma – Santa Catarina, Brazil

2019 ◽  
Vol 52 (2) ◽  
pp. 104-109
Author(s):  
Ives Alexandre Yutani Koseki ◽  
Matheus Rosso Benedet ◽  
Guilherme De Sá ◽  
Rafael De Conti ◽  
Roberto Meister Bernardi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Positive Predictive Value ◽  
Prostate Specific Antigen ◽  
Predictive Value ◽  
Odds Ratio ◽  
Specific Antigen ◽  
Digital Rectal Examination ◽  
Case Group ◽  
Rectal Examination ◽  
The Impact

Background: Prostate cancer is the second most incident of the male population in Brazil. The aim of this study is to analyze the frequency of risk factors associated to the evolution of the prostate cancer and the impact of conducting examinations in the age range (55-69 years old), in assisting health professionals to manage and prevent the disease. Methods: A case-control study was performed on patients from 2011 to 2016 in Criciúma – SC, Brazil. The sample was divided into two groups, one with biopsy for prostate adenocarcinoma (case; n = 124) and the other with a negative biopsy (control; n = 251). The following variables were compared between the two groups: age, family history of prostate cancer, prostate specific antigen, and altered digital rectal examination. Results: In the case group, ranging between 55-69 years old, there was a significant higher of altered digital rectal examination (p < 0.001, odds ratio 15.5 and positive predictive value 91.3%), prostate-specific antigen ≥ 4 ng/mL (p < 0.001, odds ratio 7.02 and positive predictive value 56.2%) and when both exams were altered (p < 0.001, odds ratio was 19.63 and the positive predictive value was 90.5%). Conclusion: This findings show that, mainly between 55-69 years old, there is a significant correlation between positive biopsy, altered digital rectal examination, and PSA ≥ 4 ng/mL.

Sign in / Sign up

Export Citation Format

Share Document